ArticleIn vivo (Athens, Greece)
Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimAdjuvant pembrolizumab is an important postoperative treatment option for selected patients with high-risk clear-cell renal cell carcinoma. However, the implementation of adjuvant pembrolizumab in routine clinical practice remains incompletely characterized. This study evaluated the real-world use of adjuvant pembrolizumab after its approval in Japan. PATIENTS AND
methodsWe retrospectively reviewed patients who underwent surgery for renal tumors at our Institution between September 2018 and December 2025. After exclusion of those with benign tumors, non-clear-cell renal cell carcinoma, or renal metastasis from another primary malignancy, and patients treated with perioperative systemic therapy for metastatic disease, 29 patients were considered eligible for adjuvant pembrolizumab. Of these, 21 underwent surgery after pembrolizumab approval in Japan; 16 received adjuvant pembrolizumab and five did not. Clinicopathological characteristics, treatment exposure, discontinuation, safety, and disease-free survival (DFS) were evaluated.
resultsAmong the 21 post-approval patients, the reasons for not receiving adjuvant pembrolizumab included patient preference (n=2), renal function (n=1), age and dementia (n=1), and prioritization of treatment for another malignancy (n=1). Among the treated patients, the median treatment duration was 7.3 months; six completed 1 year of treatment, four remained on treatment at the data cutoff, and six discontinued treatment. Grade ≥3 adverse events occurred in five (31.3%) patients. Median DFS was not reached in the pembrolizumab-treated group and was 18.3 months in the non-pembrolizumab-treated group (
conclusionAdjuvant pembrolizumab was incorporated into real-world clinical practice for patients with high-risk clear-cell renal cell carcinoma after surgery, although not all eligible patients received treatment. Treatment discontinuation and grade ≥3 adverse events were not uncommon. Larger studies with longer follow-up are warranted to better define the real-world effectiveness and tolerability of adjuvant pembrolizumab in this setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.